{"organizations": [], "uuid": "c3917a01f10d9ae596d2cf330f11bbe66008eb62", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/legal", "section_title": "Legal News | Reuters", "url": "https://www.reuters.com/article/health-lidoderm/teva-to-pay-157-million-to-resolve-lidoderm-pay-for-delay-cases-idUSL2N1Q21H3", "country": "US", "domain_rank": 408, "title": "Teva to pay $157 million to resolve Lidoderm pay-for-delay cases", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-13T06:39:00.000+02:00", "replies_count": 0, "uuid": "c3917a01f10d9ae596d2cf330f11bbe66008eb62"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/health-lidoderm/teva-to-pay-157-million-to-resolve-lidoderm-pay-for-delay-cases-idUSL2N1Q21H3", "ord_in_thread": 0, "title": "Teva to pay $157 million to resolve Lidoderm pay-for-delay cases", "locations": [], "entities": {"persons": [{"name": "endo", "sentiment": "none"}], "locations": [], "organizations": [{"name": "teva pharmaceuticals ltd", "sentiment": "negative"}, {"name": "teva", "sentiment": "negative"}, {"name": "endo international plc", "sentiment": "none"}, {"name": "watson pharmaceuticals inc", "sentiment": "none"}, {"name": "u.s. securities and exchange commission", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Teva Pharmaceuticals Ltd said on Monday it would pay $157 million to resolve lawsuits alleging a drugmaker whose business it later acquired was paid by Endo International Plc to delay launching a generic version of Endoâ€™s Lidoderm painkiller patch.\nTeva disclosed in a filing with the U.S. Securities and Exchange Commission that it would pay the sum to settle claims stemming from litigation against Watson Pharmaceuticals Inc, whose generics business Teva acquired in 2015.\nTo read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2o1QSgg\n ", "external_links": ["http://bit.ly/2o1QSgg", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T06:39:00.000+02:00", "crawled": "2018-02-13T07:52:40.009+02:00", "highlightTitle": ""}